Imatinib on target in stroke recovery

Area of Science:

• Neuroscience
• Regenerative Medicine
• Pharmacology

Background:

• Ischemic stroke leads to central nervous system (CNS) scarring that hinders functional recovery.
• Myofibroblasts and the platelet-derived growth factor (PDGF) pathway are implicated in stroke pathology.
• There is a critical need for therapeutics to enhance recovery after the acute phase of stroke.

Purpose of the Study:

• To investigate the therapeutic potential of inhibiting the PDGF pathway for improving functional recovery after ischemic stroke.
• To determine if targeting PDGF-CC or its receptor PDGFRα can reduce scar formation and enhance recovery.

Main Methods:

• The study utilized a mouse model of ischemic stroke.
• Inhibition of PDGF-CC or its receptor, PDGFRα, was administered.
• Functional recovery and myofibroblast populations were assessed post-treatment.

Main Results:

• Inhibition of PDGF-CC or PDGFRα significantly reduced the myofibroblast population in the stroke scar.
• PDGFRα inhibition led to improved functional recovery in mice after ischemic stroke.
• Therapeutic effects were observed even when PDGFRα inhibition was initiated 24 hours after stroke.

Conclusions:

• Targeting the PDGF pathway, specifically PDGFRα, holds therapeutic potential for enhancing functional recovery after ischemic stroke.
• Inhibition of PDGFRα is effective even when initiated in the later phase after stroke, suggesting a viable treatment window beyond the acute phase.
• This research opens avenues for developing novel therapeutics to improve long-term outcomes for stroke survivors by addressing scar-mediated recovery deficits.